Revolution Medicines Inc annual operating income for fiscal TTM was -$1.4 billion, a decrease of 17.3% from -$1.2 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Operating Income (annual) | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (EBIT) | ($1.4B) | ($1.2B) | ($690M) | ($487M) | ($258M) | ($188M) | ($111M) | ($54M) | ($40M) | ($31M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Operating Income (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| Operating Income (EBIT) | ($445M) | ($362M) | ($315M) | ($265M) | ($241M) | ($216M) | ($176M) | ($157M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More RVMD metrics: Revenue · Gross Profit · Net Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding
All RVMD financial statements → Interactive RVMD charts →
About TickerBase · Data methodology & sources